Selvigaltin (GB1211), an orally accessible small molecule galectin-three inhibitor developed being a therapy for liver fibrosis and cirrhosis, was evaluated to assess the influence of hepatic impairment on its pharmacokinetics and safety to handle regulatory requirements. Table four Statistical assessment of dose proportionality of your pharmacokinetic parameters of GB1211 adhering https://cruzyiten.activablog.com/38333311/5-easy-facts-about-gb1211-described